• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Compounds having the formula: <IMAGE> wherein (a) when R1 is -COCH3 or -COCH2OH, R2 is -OH, R3 is -OCH3 and R4 is -H; (b) when R2 is -COCH3 or -COCH2OH; R1 is -OH, R3 is -H and R4 is -OCH3; and which are useful in treating certain mammalian tumors, are prepared from 9,10-anhydro-N-trifluoroacetyl daunorubicin, a known compound.
    公开号:SU867315A3
    申请号:SU792763508
    申请日:1979-05-08
    公开日:1981-09-23
    发明作者:Пенко Серджио；Гоцци Фаусто；Ангелуччи Франческо；Аркамоне Федерико
    申请人:Фармиталиа Карло Эрба С.П.А. (Фирма)；
    IPC主号:
    专利说明:

    The invention relates to a process for the preparation of new chlorohydrates of substituted anthracyclines possessing valuable. mi antitumor properties. The reaction of tetracycline aglycones with the derivatives of daunosamine 1 is known. The purpose of the invention is to obtain new compounds that expand the arsenal of effects on a living organism. This goal is achieved by the preparation of substituted anthracyclines chlorohydrates of the general formula: COCHj group or COCH / OH-, OH; R — OCHjf R — H, —COCHj or COCHijOHj or R —OH group; R - H; R - OCHj ,, is included in the fact that 9,10-anhydrous N-trifluoroacetyl daunomycin for O OH NHtOCF, dissolved in methyl alcohol, is first reduced by sodium cyanoborohydride in the presence of 0.1N. aqueous hydrochloric acid and iri at room temperature to the corresponding 9, 10-anhydro-13-dihydro-N-trifluoroacetyldaunomycin of the formula OH. SNONSN,
    then a solution of compound III in chloroform is epoxidized with methachloroperbenzoic acid, at the boiling point of the reaction mixture for 3-3.5 hours, to obtain 9-deoxy-9,10-epoxide-13-dihydro-N-trifluoroacetyldaunomycin as a mixture of zpimeric epoxides, which are reacted with dimethylsulfoxide and dicyclohexylcarbodiimide using pyridinium trifluoroacetate as a catalyst to obtain 9-deoxy-9,10-epoxide daunicinone of the formula
    ABOUT
    About him
    which, in turn, is treated with methyl alcohol by boiling the reaction mixture for 15 hours in the presence of a catalytic amount of p-toluenesulfonic acid, the resulting mixture is separated by chromatography on a silica gel column and using ethyl acetate / toluene as an eluting solvent and petroleum ether (3: 2: 2 v / v) to produce epimeric 10-methoxy-daunomycin by formula V and 9,10-di-10-methoxy-daunomycinone of formula VI
    About him
    HE
    OH OH, 0 (On - OH
     COCHj
    Si
    OH he
    the compounds Y or VI are reacted in anhydrous methylene chloride with 1-chloro-N, 0-trifluoroacetyl daunosamine in the presence of an ethereal solution of silver trifluoromethanesulfonate. used as a catalyst, to obtain the corresponding N, O-protected trifluoroacetyl glucosides, then 0-trifluoro-detyl rpyfiny protecting is sequentially cleaved by reaction with methanol at room temperature for 5 h and split off by N-protecting trifluoroacetyl group by 0.1N hydrolysis. aqueous sodium hydroxide for 30 minutes at 0 ° C, resulting in 10-methoxydaunomycin and 9,10-diopy-10-methoxydaunomycin being obtained and isolated as chlorohydrates; these glucosides in chloroform are then reacted with bromine to give their corresponding 14-bromo-derivatives; the bromo derivatives are hydrolyzed at room temperature for 100 h with sodium silicate to obtain, respectively, 10-methoxy-adriamycin and 9,10-diepi-10-methoxyadriamycin, which are isolated in the form of their chlorohydrates.
    Anthracyclinones V and V /, which were previously unknown, are used as starting reagents for the production of new glucosides. They are synthesized from 9,10-anhydrous-N-trifluoroCetyl-daunorubicin of formula VII.
    In order to carry out epoxidation of conjugated double bonds at C-9 and C-10 in compound VII, the ketone functional group is first reduced to the corresponding oL, ft of unsaturated alcohol. Recovery using sodium cyanoborohydride in an acceptable water-miscible organic solvent such as dioxane or dimethoxyethane in the presence of a mineral acid yields a corresponding 13-dihydro derivative of the formula Viit in quantitative yield. This compound is then subjected to an epoxidation reaction using m-chloroperbenzoic acid in an aprotic solvent, such as methylene chloride, chloroform or acetone.
    The epoxidation reaction proceeds in the temperature range from 25 to, with the formation of 9,10-epoxy-13-dihydro-N-trifluoroacetyldaunorubicin of formula X as an epimeric mixture. The regeneration of the ketone functional group with simultaneous cleavage of the glucoside bond is carried out by oxidation with dimethyl sulfoxide and dicyclohexylcarbodiimide, using pyridinium trifluoroacetate as a catalyst. The yield of the oxidation reaction is determined by the amount of catalyst: when the substance to salt ratio is 1: 1 with a high yield, a compound of the formula x is obtained.
    Subsequent introduction of the methoxyl group, which is achieved by opening the oxirane ring of compound X with methyl alcohol in the presence of a catalytic amount of para-toluenesulfonic acid, allows to obtain a mixture of aglycons of formulas V and VI in the ratio of 7: 2 (approximately). This mixture was chromatographed on silica gel. Compounds V and VI differ stereochemically at the C-9 and C-10 centers. In fact, only compound V gives a 7,9-isopropylidene derivative of the formula) (by treatment with 2,2-dimethoxypropane, with hydroxyl groups at C-7 and C-9 in position.
    The NMR spectrum of compounds .V and VI showed that C-10 N has an equagorial orientation in compound V and an axial orientation in compound VI. Treatment of Compound VI with 2,2-dimethoxy-propane gives 7-methoxy-9,10-di-10-methoxy-daunomycinone of formula X1. The reaction of combining the above carbon monoxide of formulas V and VI with N, O-protected with a halogenated sugar of the formula to form a glucoside bond is carried out in an acceptable organic solvent such as chlorofor methylene chloride, tetrahydrofuran, in the presence of a silver salt, which is with the catalyst. Thus, the resulting N.O.-protected glucoside is first treated with methyl alcohol to remove the 0-protecting tofluoroacetyl group from the sugar residue, resulting in N-protected glucose IDs VIV and XV. These products are converted by mild alkaline treatment to a quantitative yield of 10 methoxy daunorubicin and 9,10-depi-10 methoxy daunorubicin (target products, where R COCH3; R rt ° OCH3: R H; R OH; R COH3; R H; R Oshg,). The other two analogues of doxorubicin are obtained from the above targeted products through their 14-bromo derivatives. The novel compounds of formula I possess antitumor activity and can be used as therapeutic preparations for treating tumor diseases in mammals. Example 1. 9,10 anhydro-.13 dihydro-m-trifluoroacetyldaunorubicin of formula V11I. In 2000 ml of methyl alcohol, 6.0 g (10 mmol) of 9DO-anhydro-N-trifluoroacetyl-daunorubicin of the formula VU is dissolved. PacTBOD is acidified with 50 ml of a 0.1 solution of hydrochloric acid in water and then reacted with an aqueous solution of NaCNBH (4.0 g in 200 mN, O). The reaction mixture is stirred at room temperature for 48 h, keeping the pH below 4 by adding 0.1 n. hydrochloric acid. After neutralization with an excess of solid sodium bicarbonate, the solution is evaporated to dryness in vacuo, and the residue, dissolved in chloroform, is washed with water. The chloroform solution was dried over anhydrous sodium sulfate, and the solvent was finally removed in vacuo to obtain the crude compound Vlil. Pure 9,10-anhydro-13-dihydroN-trifluoroacetyl-daunorubicin is obtained by chromatographic purification on a column with silicic acid, using chloroform-acetone system (95: 5 v / v) as an eluting solvent. The product melts at (with decomposition). The absorption maxima in the visible spectrum (SSCC) are at 520 and 556 µm. Example 2. Synthesis of 9-deoxy9, 10-epoxide-13-dihydro-N-trifluoroacetyldaunorubicin of formula IX. To a solution of 8 g (13.28 mmol) of 9.10 anhydro-13-dihydro-N-trifluoroacetyl daunomycin of formula V / C in 400 ml of chloroform was added 1.08 g (6 mmol) of meta-chloro benzoic acid and the reaction mixture was kept at reflux for 3 hours. The initial cherry color of the solution gradually changes to red. The reaction mass is then cooled and washed with an aqueous NaHCOgi solution of water, and dried over anhydrous sodium sulfate. The solvent is evaporated to dryness in vacuo. The residue (2.0 g) with a maximum in the spectrum; three visible light (CHClg) at 490, 504, 540 µm (which is consistent with the disappearance of the double bond at C-9, C-10 of Vif) are epimeric epoxides and applied in psychosocial hardeners without further purification. Example 3. 9-Deoxy-9,10 epoxide-daunomycinone of formula X. To a stirred solution of 3.85 g (6 mmol) of 9-deoxy-9,10-zpoxide 13-dihydro-N-trifluoroacetylamine of formula IX in 100 ml of anhydrous dimethyl sulfoxide in a nitrogen atmosphere, successively add 3.8 g (18 units) of dicyclohexylcarbodiimide, 0 , 5 ml (6 madol) of anhydrous pyridine and 0.23 ml (3 mmol) of trifluoroacetic acid. The mixture is stirred at room temperature for 15 minutes, then diluted with 500 ml of chloroforium. Chloroform solution vains. but washed with water, dried and evaporated to dryness. The residue is dissolved in ethyl acetate, insoluble dicyclohexylurea is filtered off and the filtered solution is evaporated to dryness, yielding compound X in quantitative yield. IR spectrum: 1720 cm-1580 and 1620 cm quinone. NMR spectrum (CDCU) cr: at 2.27. (1, SNg-C 0) 4.10 (singlet, OGHj) and 4.81 L1, H-10). PRI and ME 4. Synthesis of 10-methoxy-daunomi .qingone of the formula V and 9,10dipi-10-methoxy-daunomycinone of the formula VI. A solution of 4.3 g of 9-deoxy-9,10-epoxide-daunomycinone of formula X in 500 ml of anhydrous methyl alcohol is heated at reflux for 15 hours in the presence of a catalytic amount of p-toluenesulfonic acid. The reaction mixture is then cooled and evaporated to dryness. The residue is dissolved in 300 ml of chloroform, washed with water. 5% sodium bicarbonate solution, water, dried over anhydrous sulphate atri and evaporated to dryness. Crude material is a mixture of compounds Y and V / in the ratio of 7: 2, while licensing. It is subjected to chromatographic. separation of the silica column using a mixture of ethyl acetate, toluene and petroleum ether (3: 2: 2 v / v) as the eluting substance. 1.5 g of the pure compound of the formula V and 0.42 g of the pure compound of the formula Y / s are obtained in a 72% yield of 10 methoxy daunomycinone of the formula y. T pl. 22oPc (with decomposition). +206 (with 0.1, СНС1e). Mass spectrum: t / e 428 (M), 396 (M-CH 3 OH), 353 (M-CHaOH-CHjCO) J NMR (CDCU) shL: 3.51 (singlet, C-lO-dCHj); 4.66 (doublet, C-10 H) j 5.31 (quadruplet, C-7H), 13.6 and 14, (singlet, OH of phenol). 9,10-diepi-10-methoxy-daunomycin of formula VI; 15bs (with decomposition) ,. Mass spectrum: т / е 428 (М). NMR spectrum (CDCl 3): 3.64 (syn-Clet, C-10-OCH, j) j 4.89 (singlet, C10H), 5.12 (quadruplet, C-7H), 13.8 and 14.21 (singlet, phenol OH). Example 5. 7,9-Isopropylidene-10-methoxydaunomycinone formula XI. To a solution of 0.1 g of compound VII in 10 ml of anhydrous dioxane is added 5 ml of 2,2-dimethoxypropane and a catalytic amount of p-toluenesulphonic acid. The reaction mixture was withdrawn. live at 50 ° C for 48 hours, then diluted with 50 ml of chloroform and washed with aqueous saturated sodium bicarbonate solution, water, and dried over anhydrous sodium sulfate. The crude residue obtained by evaporation of the organic solvent is chromatographed on a column of silica acid, using a mixture of chloroform and acetone as an eluting solvent in the ratio of 95–5 / v. A 7.9-isopropylidene-10-methoxy-nomininone of formula XI is obtained. Mass spectrum of the product: т / е 468 (М-) 410 (М- (СНз) о, СО) 378 (М- (СНа) 2СО-СНо, ОН). NMR- (COCl3) SL: 1.2 and 2.47 (singlet, 2CHj) -, 5.47 (multiplet, C-7H Example 6. 7-Methoxy-9,10dipi-10-methoxy-daunomycinone Formula XII. Treatment of the compound VI 2,2-dim tokenization in accordance with the method of diet (th. Of example 5 get 7-methoxy-9, 10-DIEPI-10-methoxydaunomycinone formula XV. Mass spectrum: t / e 422 () -i Example 7. Synthesis of hydrochloride 10-methoxy-daunorubicin MAP 87. To a solution of 0.43 g (1 mmol) of 10-metoxidaunomycinone of formula Y in 200 ml of anhydrous methyl chloride, 0.43 g (1.2 mmol) of 1-chloro-N, 0-trift6-racetylda-amine is added. for Yu min at ko 0.32 g (1.2 mmol) in 26 ml of anhydrous sulfuric ether is added to the reaction temperature. Then 0.2 ml (1.4 mmol) of anhydrous ethylmethylpyridine are added to the reaction mixture. After 40 min, the mixture is treated with a saturated aqueous solution The sodium bicarbonate and the separated organic phase are evaporated in vacuo. The residue is dissolved in 100 ml of methanol and kept at room temperature for 5 hours. The residue, which is obtained by removing the solvent, is purified by chromatographic silica gel column using a mixture of chlorine. roforma and acetone in a ratio of 4: 1 v / v as eluting solvent.. In addition to the unreacted compound V, 0.26 g of pure 10-methoxy-N trifluoroacetyldaunorubicin of formula I is obtained. M.p. product 190 ° C (with decomposition). Carry out thin layer chromatography on a Kieselgel F (Merck) plate using a solvent system of chloroform and acetone (4: 1 v / v. R 0.3); NMR spectrum (COCl3) cA: 1.30 (doublet, CH 2, -CH) V 3.52 (singlet, C-10 AXIS); 5.30 (multiplet, C - 7H) and 5.53 (multiplet, C-1 - HcixWH 7 Hz). 10-Methoxydunorubicin (0.26 g) is dissolved in 0, -1N. aqueous sodium hydroxide (50 ml) and after holding it at 0 ° C for 30 minutes, the pH of the solution is adjusted to 8.6 and the solution is re-extracted with chloroform. The combined extracts, dried over anhydrous sodium sulfate, are concentrated to a small volume and acidified to pH = 4.5 with 0.1 N. methanol hydrogen chloride, as a result of which crystalline - is isolated; t-hydrochloride U-methoxidaunorubicin. T. pl. 159 ° С (with decomposition). + 316 (with 0.05, SNZON); thin layer chromatography on a Kieselgel plate (Merck) using a system of chloroform, methyl alcohol and water (13: 6: 1 v / v) as a solvent. Rf 0.37. Example 8. 9,10-depi-10methoxy-daunorubicin MAR 96. By performing a coupling reaction between the anthracyclone of the formula V) and 1gllorN, 0-trifluoroacetyldaunosamine, as described in Example 7v, 9.10 di-10-methoxy-N -trifluoroacetyldaunorubicin is obtained, after which alkali mild processing 0.1 n. aqueous sodium hydroxide for 30 minutes, 10-depi-10-methoxy-daunorubicin is obtained as the hydrochloride. The product has t.
    square 140С (with decomposition). + 252 (C 0.05, CHjOH).
    Example 9. Synthesis of 10-methoxy-doxorubicin MAR 95.
    Pac-FBOp 10-methoxydaunorubicin in a mixture of methyl alcohol and dioxane is treated with bromine, resulting in its 14-bromine visible, followed by treatment with an aqueous solution of sodium formate at room temperature for 100 hours to obtain 10-methoxy-doxorubicin, which is isolated as hydrochloride , T. pl. (with decomposition).
    Thin layer chromatography was carried out on a Kieselgel (merk) HF254 plate using
    Antitumor activity
    10 (R) -methoxyoxoxorubicin and 9,10-depi 10-methoxy-daunorubicin versus daunorubicin and doxorubic activity
    a solution to the mixture system of chloroform, methyl alcohol, water, and acetic acid (8: 2: 0.6: 1.4 v / v) Rf - 0.45.
    . Example 10. Synthesis of 9,10 depi-10-1 "yutoxidoxorubicin.
    As in Example 9, by treating 9,10-depi-10-methoxy-daunorubicin with bromine and then with sodium formate, 9,10-diepi-10-mettq oxorubicin of the formula YI, which is listed as hydrochloride, is obtained.
    Given in Table. the data illustrate the antitumor activity of the new anthracycline derivatives 1 &amp; against lymphocytic leukemia and P pharynx 10- (R) -methoxydaunorubicin,
    Daunorubicin
    10- (R) -Methoxidaunorubicin
    Doxrrubicin
    10- (R) -Metoxidoxorubicin
    9,10-Dispi-10-methoxydounor Ubicin
    90 98
    119
    124 133
    115 110
    108 171 133 129 119
    104 115 127 125 108
    126 132 118 102
    Compounds were tested in vivo in SDH mice scavenged with tumor cells. After transplantation of the tumor to the tumor on 5.9 and 13th days, they were administered intraperitoneally injections (a four-day break after each injection). The average duration of survival as a percentage of the B / K control group,% is given in the table.
    权利要求:
    Claims (1)
    [1]
    Invention Formula
    The method of producing chlorohydrates of substituted anthracyclines of the general formula
     he "vv
    where R is the group COCH j or COCH, OH; R is OH; R - OSS: R - H i
    R;
    R- - group SOSNO or SOSN.ON;
    or r
    R is OH; R - H; R = OSI, characterized in that 9,10-anhydrous-N-trifluoroacetyldaunomycin of formula II
    OH9
    GS-CH,
    BUT
    NHtOtF
    de a mixture of epimeric epoxides, which are reacted with dime |: tylsulfoxide and dicyclohexylcarbodiimide in the presence of a trifluoroacetate pyridinium catalyst, to obtain 9-deoxy-9,10-epoxy-daunomycinone of formula IV
    oh he ochj
    oh he nosn
    Uh
    COCHj I
    oh he he
    1386731514
    V .. sodium sulfate to obtain the corresponding-sources of information,
    10-methoxy-adriamycin and 9,10-taken into account in the examination of diepi-10-methoxy-adriamycin, which are 1. Patent of the USSR 583763,
    are isolated in the form of their chlorohydrates. C 07 H 15/24, published 05.12.77.
    类似技术:
    公开号 | 公开日 | 专利标题
    JP2651414B2|1997-09-10|4-dementoxy-4-amino-anthracyclines
    US4020270A|1977-04-26|L-lyxohex-1-enopyranose derivative
    US4067969A|1978-01-10|Anthracycline glycosides, their preparation and use
    US4112076A|1978-09-05|Epi-daunomycin and epi-adriamycin compounds and method of use
    US4366149A|1982-12-28|Antitumor anthracycline glycosides, their preparation, intermediates therefor, and compositions and use thereof
    SU867315A3|1981-09-23|Method of preparing substituted anthracycline chlorohydrates
    US4325946A|1982-04-20|Anthracycline glycosides, their preparation, use and compositions thereof
    EP0199920B1|1988-08-17|New antitumor anthracyclines
    EP0051279B1|1985-09-04|Anthracycline glycosides, intermediate compounds, process for preparing both and pharmaceutical compositions
    US4839346A|1989-06-13|Antitumor anthracycline glycosides, intermediates thereof, and composition and use thereof
    CA1090788A|1980-12-02|Process for the preparation of antitumor glycosides
    US4322412A|1982-03-30|Anthracycline glycosides, their preparation, use and compositions thereof
    JP2516769B2|1996-07-24|New anthracyclines
    US4749693A|1988-06-07|Nitro anthracyclines, process for their preparation and use thereof
    RU2073681C1|1997-02-20|Anthracycline glycoside and method of its synthesis
    US4265885A|1981-05-05|Anthracyclines containing branched-chain amino-deoxy sugars
    US5045534A|1991-09-03|4-demethoxy-4&#39;-amino-4&#39;-deoxy-anthracycline derivatives
    RU2095365C1|1997-11-10|8-fluoroanthracycline glycosides or pharmaceutically acceptable acid addition salts thereof, method of preparation thereof, pharmaceutical composition, intermediate compounds, and method of preparation thereof
    OGAWA et al.1984|THE ABSOLUTE STRUCTURES OF RUBEOMYCINS A AND A1 | AND RUBEOMYCINS B AND B1 |
    GB2215332A|1989-09-20|4-Demethyl-4-0-| anthracycline glycosides
    KR900007318B1|1990-10-08|Process for preparing 4&#39;-epidoxorubicin
    US5412081A|1995-05-02|New 4&#39;-epi-4&#39;-amino anthracyclines
    KR920000620B1|1992-01-17|New anthracycline glycosides derivatives
    CA1091657A|1980-12-16|New antitumor agent 9-deacetyl-9 ethylene oxyde daunorubicin hydrochloride
    SU1277902A3|1986-12-15|Method of producing 4&#39;-deoxy-daunorubicyn or 4&#39;-deoxy-doxorubicyn
    同族专利:
    公开号 | 公开日
    IE790906L|1979-11-09|
    NL7903539A|1979-11-13|
    US4216157A|1980-08-05|
    AU528439B2|1983-04-28|
    JPS5513264A|1980-01-30|
    IL57219A|1982-12-31|
    IE48371B1|1984-12-26|
    ATA340879A|1980-12-15|
    GB2021571B|1982-09-29|
    DE2918291A1|1979-11-15|
    NO791520L|1979-11-12|
    AT363186B|1981-07-10|
    NO147310C|1983-03-16|
    CA1128503A|1982-07-27|
    HU180298B|1983-02-28|
    IL57219D0|1979-09-30|
    ZA792177B|1980-05-28|
    NO147310B|1982-12-06|
    FR2425446B1|1982-07-30|
    YU105279A|1982-10-31|
    IT1098212B|1985-09-07|
    CS207789B2|1981-08-31|
    IT7823151D0|1978-05-09|
    GB2021571A|1979-12-05|
    BE876099A|1979-11-08|
    FR2425446A1|1979-12-07|
    US4199571A|1980-04-22|
    SE7903972L|1979-11-10|
    CH640869A5|1984-01-31|
    AU4668479A|1979-11-15|
    US4229355A|1980-10-21|
    DK188079A|1979-11-10|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US3201424A|1962-10-29|1965-08-17|American Cyanamid Co|Derivatives of 1, 3, 11, 12-tetrahydroxynaphthacene and 1, 3, 6, 11-tetrahydroxynaphtacene-5, 12-quinone|
    US3803124A|1968-04-12|1974-04-09|Farmaceutici It Soc|Process for the preparation of adriamycin and adriamycinone and adriamycin derivatives|
    US3686163A|1968-05-14|1972-08-22|Farmaceutici Italia|Dihydrodaunomycin antibiotic and derivatives thereof|
    FI51808C|1968-07-15|1977-04-12|Rhone Poulenc Sa|Method for the preparation of naphthacene derivatives of new tumors.|
    US4020270A|1974-05-02|1977-04-26|Societa' Farmaceutici Italia S.P.A.|L-lyxohex-1-enopyranose derivative|
    GB1461190A|1974-09-20|1977-01-13|Farmaceutici Italia|Anthracycline preparation|
    US4133877A|1976-07-08|1979-01-09|Societa Farmaceutici Italia S.P.A.|Anthracycline ethers and use therefor|
    GB1561719A|1976-12-22|1980-02-27|Farmaceutici Italia|Anthracyclines|IT1210476B|1981-05-28|1989-09-14|Erba Farmitalia|ANTHRACYCLINES.|
    US4563444A|1982-05-26|1986-01-07|Farmitalia Carlo Erba S.P.A.|Anthracycline glycosides, use and compositions containing same|
    IT1155446B|1982-12-23|1987-01-28|Erba Farmitalia|PROCEDURE FOR THE PURIFICATION OF ANTHRACYCLINONIC GLUCOSIDES BY SELECTIVE ADSOBMENT ON RESINS|
    US4489206A|1983-05-13|1984-12-18|Adria Laboratories, Inc.|Synthesis of -4-demethoxydaunomycinone|
    JPH0528280Y2|1986-12-10|1993-07-20|
    WO2004087097A2|2003-03-31|2004-10-14|Yissum Research Development Company Of The Hebrew University Of Jerusalem|Stable liposomes or micelles comprising a sphinolipid and a peg-lipopolymer|
    US20080058274A1|2004-11-15|2008-03-06|Yechezkel Barenholz|Combination Therapy|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    IT23151/78A|IT1098212B|1978-05-09|1978-05-09|REPLACED ANTI-CANCER ANTHRACIOLINES|
    [返回顶部]